Sign In
Buy RCUS
$28.42
-1.31 (-4.41%)
At Close: Jul 24, 2026
Arcus Biosciences, Inc. (RCUS) Q4 2025 Earnings Call Transcript
11:17pm, Wednesday, 25'th Feb 2026
Arcus Biosciences, Inc. (RCUS) Q4 2025 Earnings Call Transcript
Arcus Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides a Pipeline Update
04:05pm, Wednesday, 25'th Feb 2026
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules for patients with cancer and in
Arcus Biosciences to Host Conference Call to Discuss Fourth-Quarter and Full-Year 2025 Financial Results and Pipeline Updates
04:05pm, Wednesday, 11'th Feb 2026
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patient
Rapid Innovation is Reshaping Oncology: Stocks in Focus
09:01am, Thursday, 05'th Feb 2026
Rapid advances in immunotherapy, targeted drugs & artificial intelligence-driven research are reshaping oncology, spotlighting select cancer stocks to watch now.
Wall Street Analysts See a 57.56% Upside in Arcus Biosciences (RCUS): Can the Stock Really Move This High?
10:56am, Wednesday, 04'th Feb 2026
The average of price targets set by Wall Street analysts indicates a potential upside of 57.6% in Arcus Biosciences (RCUS). While the effectiveness of this highly sought-after metric is questionable,
Arcus Biosciences Announces New Employment Inducement Grants
04:35pm, Monday, 26'th Jan 2026
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p
Arcus Biosciences, Inc. (RCUS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
08:55pm, Wednesday, 14'th Jan 2026
Arcus Biosciences, Inc. (RCUS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Arcus Outlines 2026 Plans for Casdatifan, its Potential Best-in-Class HIF-2a Inhibitor, and its Inflammation Programs
04:05pm, Wednesday, 07'th Jan 2026
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules for patients with cancer and in
Arcus Biosciences President Sells $2 Million as Stock Delivers 48% Annual Return
09:04pm, Monday, 05'th Jan 2026
82,997 shares were sold indirectly on Dec. 4, 2025, for a transaction value of ~$2.1 million based on a weighted average sale price of $24.71 per share. The sale represented 5.91% of total holdings, l
Robert Goeltz II Sells 6,552 Shares of Arcus Biosciences (NYSE:RCUS) Stock
04:16am, Sunday, 04'th Jan 2026
Arcus Biosciences, Inc. (NYSE: RCUS - Get Free Report) CFO Robert Goeltz II sold 6,552 shares of the firm's stock in a transaction on Wednesday, December 31st. The stock was sold at an average price o
Arcus Biosciences to Participate in the 44th Annual J.P. Morgan Healthcare Conference
04:05pm, Thursday, 18'th Dec 2025
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patient
Arcus Biosciences: Casdatifan Takes Center Stage After STAR-221
09:02am, Wednesday, 17'th Dec 2025
RCUS is now resetting its strategy after its Phase 3 STAR-221 was discontinued. This removes domvanalimab for upper-GI cancers as a key catalyst. Instead, they'll focus now on Casdatifan (AB521), whic
RCUS Stock Down on Decision to Discontinue GILD Partnered Study
11:01am, Monday, 15'th Dec 2025
Arcus halts the late-stage STAR-221 study for futility, dealing a setback to its domvanalimab program with Gilead. Stock down.
Arcus Revamps Cancer Pipeline Following Trial Miss, Prioritizes Kidney Drug
01:35pm, Friday, 12'th Dec 2025
Arcus Biosciences, Inc. (NYSE:RCUS) on Friday announced the discontinuation of the Phase 3 STAR-221 study, being conducted in partnership with Gilead Sciences, Inc. (NASDAQ: GILD), due to futility.
